期刊文献+

左心疾病所致的肺动脉高压大鼠模型的制备方法 被引量:2

The method of establishing rats model of pulmonary hypertension associated with left heart diseases
暂未订购
导出
摘要 目的探讨左心疾病所致的肺动脉高压(PH-LHD)大鼠模型的制备方法。方法雄性未成年SD大鼠行冠状动脉开口以上的升主动脉缩窄手术来获得PH-LHD大鼠模型。模型组造模成功后分别在术后第1、3、5、8、15、22、36、50、64天进行体动脉压、右心室压监测。实验以第0天未经处理的大鼠及在第64天行假手术的大鼠作为对照。结果 SD大鼠行升主动脉缩窄手术后第64天,成功获得PH-LHD模型,表现为体动脉压力没有改变,右心室压力升高。结论冠状动脉以上的升主动脉的缩窄术是制作PH-LHD动物模型的理想方法。 Objective To discuss the method of establishing rats model of pulmonary hypertension associated with left heart diseases. Methods Juvenile SD rat model of PH - LHD was induced by supracoronary aortic banding. On dl, d3, dS, d8, d15, d22, d36, dS0, d64 after treatment, artery pressure and right ventricular pressure was chronologically collected. Rats without any treatment on dO and rats undergone sham operation on d64 were used as controls. Results On d64, unchanged artery pressure and increased right ventricular pressure were observed, indicating rat model of PH - LHD was successfully induced. Conclusion Supracoronary aortic banding is an ideal treatment to establish PH - LHD rat model.
作者 张蕙 陈良万
出处 《临床和实验医学杂志》 2014年第5期352-355,共4页 Journal of Clinical and Experimental Medicine
基金 国家临床重点专科建设项目经费资助 福建省临床重点专科建设项目资助
关键词 大鼠 左心疾病所致的肺动脉高压 模型 Rats Pulmonary hypertension associated with left heart diseases Model
  • 相关文献

参考文献2

二级参考文献33

  • 1O'kanke H O,J Thorac Cardiovasc Surg,1973年,65卷,2期,264页
  • 2Kiyoko Takemiya,Hisashi Kai,Hideo Yasukawa,Nobuhiro Tahara,Seiya Kato,Tsutomu Imaizumi.Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats[J]. Basic Research in Cardiology . 2010 (3)
  • 3Kawabata M,Miyazono K.Signal transduction of the TGF-beta superfamily by Smad proteins. Journal of Biochemistry . 1999
  • 4Massague J.TGF-β signal transduction. Annual Review of Biochemistry . 1998
  • 5Ramos MF,Lamé MW,Segall HJet al.Smad signaling in the rat model of monocrotaline pulmonary hypertension. Toxicologic Pathology . 2008
  • 6Long L,Crosby A,Yang X,et al.Altered bone morphogenetic protein and transforming growth factor- beta signaling in rat models of pulmonary hypertension:potential for activin receptor -like kinase-5 inhibition in prevention and progression of disease. Circulation . 2009
  • 7B Bartelds,RL Loon,S Mohaupt,H Wijnberg,M Dickinson,B Boersma,J Takens,M Albada,RM Berger.Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest . 2012
  • 8S. Um ar,Y. P. de Visser,P. Steendijk, et al.Allogenic stem cell therapy improves rightventricular function by improving lung pathology in rats with pulmonary hypertension. AmericanJournal of Physiology . 2009
  • 9Liang OD,Mitsialis SA,Chang MS, et al.Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells . 2011
  • 10Kanki-Horimoto S,Horimoto H,Mieno S, et al.Implantation of mesenchymalstem cells overexpressing endothelial nitric oxide synthase improves right ventricularimpairments caused by pulmonary hypertension. Circulation . 2006

共引文献8

同被引文献24

  • 1张曼,屈晨,曾定尹.Rho/Rho激酶在压力负荷心力衰竭大鼠心肌组织的表达[J].中华心血管病杂志,2005,33(1):73-76. 被引量:52
  • 2Raja SG, Dreyfus GD. Current status of bosentan for treatment ofpulmonary hypertension [ J]. Ann Card Anaesth,2008,11:6-14.
  • 3Duong-Quy S, Bei Y , Liu Z, et al. Role of Rho-kinase and itsinhibitors in pulmonary hypertension [J]. Pharmacol Ther,2013,137: 352 -364.
  • 4Nagaoka T, Gebb SA, Kaxoor V,et al. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hood-ed rat [ J]. J Appl Physiol,2006, 100: 996 - 1002.
  • 5Nagaoka T, Morio Y , Casanova N , et al. Rho/Rho kinase signa-ling mediates increased basal pulmonary vascular tone in chroni-cally hypoxic rats [ J ] . Am J Physiol Lung Cell Mol Physiol,2004, 287: L665 - L672.
  • 6Hyvelin JM, Howell K, Nichol A, et al. Inhibition of Rho-ki-nase attenuates hypoxia-induced angiogenesis in the pulmonarycirculation. Circ Res ,2005 ;97 : 185 -191.
  • 7Nagaoka T, Fagan KA , Gebb SA, et al. Inhaled Rho kinase in-hibitors are potent and selective vasodilators in rat pulmonary hy-pertension [J]. Am J Respir Crit Care Med ,2005 , 171 : 494 -499.
  • 8Barst RJ, McGoon M , Torbicki A, et al. Diagnosis and differen-tial assessment of pulmonary arterial hypertension [ J ]. J Am CollCardiol, 2004, 43: 40S-47S.
  • 9McLaughlin VV, Archer SL, Badesch DB, et ai. ACCF/AHA2009 expert consensus document on pulmonary hypertension: ureport of the American College of Cardiology Foundation TaskForce on Expert Consensus Documents and the American HearlAssociation developed in collaboration with the American Collegeof Chest Physicians; American Thoracic Society, inc. ; and thePulmonary Hypertension Association [J]. J Am Coll Cardiol,2009,53: 1573 - 1619.
  • 10Mita S , Kobayashi N , Yoshida K , et al. Cardioprotective mecha-nisms of Rho-kinase inhibition associated with eNOS and oxida-tive stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rals[J]. J Hypertens, 2005, 23; 87 -96.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部